HCV genotype 5: an orphan virus

被引：6

作者：

Antaki, Nabil ^{[1
]}

Abboud, Dirar ^{[1
]}

Antaki, Fadi ^{[2
,3
]}

Craxi, Antonio ^{[4
]}

机构：

[1] St Louis Hosp, Dept Gastroenterol & Hepatol, Aleppo, Syria

[2] John D Dingell VA Med Ctr, Dept Med, Div Gastroenterol, Detroit, MI USA

[3] Wayne State Univ, Detroit, MI USA

[4] Univ Palermo, DIBIMIS, Dept Gastroenterol & Hepatol, Palermo, Italy

来源：

ANTIVIRAL THERAPY | 2013年 / 18卷 / 03期

关键词：

CHRONIC HEPATITIS-C; INTERFERON PLUS RIBAVIRIN; IL28B POLYMORPHISMS; ANTIVIRAL EFFICACY; PROTEASE INHIBITOR; GENETIC-VARIATION; PREDICT RESPONSE; HIGH PREVALENCE; THERAPY; INFECTION;

D O I：

10.3851/IMP2449

中图分类号：

R51 [传染病];

学科分类号：

100201 [内科学];

摘要：

HCV genotype 5 (HCV-5) is the least known HCV genotype. It is found mainly in South Africa and in restricted areas of Belgium, Spain, France, Syria and Greece. Sporadic cases are reported worldwide. The main modes of transmission are blood transfusion and iatrogenic causes. Little is known about its origin, but various studies have elucidated its spread worldwide. In endemic areas, patients infected with HCV-5 are on average older and have a higher viral load and more advanced fibrosis than those infected with non-HCV-5 genotypes. The current standard of care for HCV-5 chronic infection is 48 weeks of dual therapy with pegylated interferon plus ribavirin. 'Favourable' Il28B polymorphisms are not associated with higher sustained viral response rates. Assessment of shorter duration of therapy is made difficult by the lack of identifiable baseline predictors of response. Whilst there are in vitro data showing good activity of some direct-acting antivirals and of host-targeted agents against HCV-5, no clinical trials of these molecules have yet started.

引用

页码：263 / 269

页数：7

共 45 条

[1]

The epidemiology and virology of hepatitis C virus genotype 5 in central France [J].

Abergel, A. ;

Ughetto, S. ;

Dubost, S. ;

Bonny, C. ;

Aublet-Cuvelier, B. ;

Delarocque-Astagneau, E. ;

Bailly, J. L. ;

Bommelaer, G. ;

Casanova, S. ;

Delteil, J. ;

Deny, P. ;

Laurichesse, H. ;

Odent-Malaure, H. ;

Roussel, J. ;

Peigue-Lafeuille, H. ;

Henquell, C. .

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2007, 26 (10) :1437-1446

[2]

The unexpected discovery of a focus of hepatitis C virus genotype 5 in a Syrian province [J].

Antaki, N. ;

Haddad, M. ;

Kebbewar, K. ;

Abdelwahab, J. ;

Hamed, O. ;

Aaraj, R. ;

Alhaj, N. ;

Haffar, S. ;

Assil, M. ;

Ftayeh, M. ;

Assaad, F. ;

Doghman, D. ;

Ali, T. ;

Nasserelddine, M. ;

Ali, A. ;

Antaki, F. .

EPIDEMIOLOGY AND INFECTION, 2009, 137 (01) :79-84

[3]

Efficacy of interferon plus ribavirin in the treatment of hepatitis C virus genotype 5 [J].

Antaki, N. ;

Hermes, A. ;

Hadad, M. ;

Ftayeh, M. ;

Antaki, F. ;

Abdo, N. ;

Kebbewar, K. .

JOURNAL OF VIRAL HEPATITIS, 2008, 15 (05) :383-386

[4]

IL28B polymorphisms predict response to therapy among chronic hepatitis C patients with HCV genotype 4 [J].

Antaki, N. ;

Bibert, S. ;

Kebbewar, K. ;

Asaad, F. ;

Baroudi, O. ;

Alideeb, S. ;

Hadad, M. ;

Abboud, D. ;

Sabah, H. ;

Bochud, P. -Y. ;

Negro, F. .

JOURNAL OF VIRAL HEPATITIS, 2013, 20 (01) :59-64

[5]

IL28B polymorphisms do not predict response to therapy in chronic hepatitis C with HCV genotype 5 [J].

Antaki, Nabil ;

Bibert, Stephanie ;

Kebbewar, Kamel ;

Asaad, Fouad ;

Baroudi, Osama ;

Alideeb, Sawsan ;

Hadad, Milad ;

Abboud, Dirar ;

Sabah, Houda ;

Bochud, Pierre-Yves ;

Negro, Francesco .

GUT, 2012, 61 (11) :1640-1641

[6]

The neglected hepatitis C virus genotypes 4, 5 and 6: an international consensus report [J].

Antaki, Nabil ;

Craxi, Antonio ;

Kamal, Sanaa ;

Moucari, Rami ;

Van der Merwe, Schalk ;

Haffar, Samir ;

Gadano, Adrian ;

Zein, Nizar ;

Lai, Ching Lung ;

Pawlotsky, Jean-Michel ;

Heathcote, E. Jenny ;

Dusheiko, Geoffrey ;

Marcellin, Patrick .

LIVER INTERNATIONAL, 2010, 30 (03) :342-355

[7]

IL28B polymorphism is associated with treatment response in patients with genotype 4 chronic hepatitis C [J].

Asselah, Tarik ;

De Muynck, Simon ;

Broet, Philippe ;

Masliah-Planchon, Julien ;

Blanluet, Maud ;

Bieche, Ivan ;

Lapalus, Martine ;

Martinot-Peignoux, Michelle ;

Lada, Olivier ;

Estrabaud, Emilie ;

Zhang, Qian ;

El Ray, Ahmed ;

Vidaud, Dominique ;

Ripault, Marie-Pierre ;

Boyer, Nathalie ;

Bedossa, Pierre ;

Valla, Dominique ;

Vidaud, Michel ;

Marcellin, Patrick .

JOURNAL OF HEPATOLOGY, 2012, 56 (03) :527-532

[8]

RESULTS OF A PROOF OF CONCEPT STUDY (C210) OF TELAPREVIR MONOTHERAPY AND IN COMBINATION WITH PEGINTERFERON ALFA-2A AND RIBAVIRIN IN TREATMENT-NAIVE GENOTYPE 4 HCV PATIENTS [J].

Benhamou, Y. ;

Moussalli, J. ;

Ratziu, V. ;

Lebray, P. ;

Gysen, V. ;

de Backer, K. ;

Ghys, A. ;

van Heeswijk, R. ;

Vangeneugden, I. ;

Picchio, G. ;

Beumont-Mauviel, M. .

JOURNAL OF HEPATOLOGY, 2009, 50 :S6-S6

[9]

Identification of numerous hepatitis C virus genotypes in Montreal, Canada [J].

Bernier, L ;

Willems, B ;

Delage, G ;

Murphy, DG .

JOURNAL OF CLINICAL MICROBIOLOGY, 1996, 34 (11) :2815-2818

[10]

Effectiveness of interferon plus ribavirin combination in the treatment of naive patients with hepatitis C virus type 5.: A French multicentre retrospective study [J].

Bonny, C. ;

Fontaine, H. ;

Poynard, T. ;

Hezodes, C. ;

Larrey, D. ;

Marcellin, P. ;

Bourliere, M. ;

Bronowicki, J. P. ;

Merle, P. ;

Zarski, J. P. ;

Sapey, T. ;

Guillemard, C. ;

Ughetto, S. ;

Henquell, C. ;

Nicolas, C. ;

Roche, C. ;

Randl, K. ;

Bommelaer, G. ;

Abergel, A. .

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2006, 24 (04) :593-600

← 1 2 3 4 5 →